Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 10/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400171 | 0.88 | TRPV4 (0.44) | TRPV4KIF11ARMRGPRX4SLC22A12 | |
| SCHEMBL26462816 | 0.84 | TRPV4 (0.41) | TRPV4KIF11ARMRGPRX4KDM4E | |
| SCHEMBL12263486 | 0.81 | TRPV4 (0.49) | TRPV4KIF11ARMRGPRX4 | |
| SCHEMBL18552864 | 0.80 | TRPV4 (0.45) | TRPV4KIF11ARMRGPRX4 | |
| SCHEMBL18552786 | 0.80 | CYP2A6 (0.35) | TRPV4GLAGAA | |
| SCHEMBL27929091 | 0.78 | TRPV4 (0.46) | TRPV4KIF11ARMRGPRX4 | |
| SCHEMBL25985277 | 0.78 | TRPV4 (0.46) | TRPV4KIF11ARMRGPRX4SLC22A12 | |
| SCHEMBL21725488 | 0.78 | IDO1 (0.39) | ALDH1A1HPGD | |
| SCHEMBL21336611 | 0.78 | CYP2A6 (0.36) | TRPV4ARALDH1A1GLA | |
| SCHEMBL24767625 | 0.77 | MEN1 (0.35) | TRPV4ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TRPV4 497/4885KIF11 4625/4885AR 413/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | TRPV4 2981/4885KIF11 3220/4885AR 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.